Varicose Veins Research Update 2026: What the Latest Evidence Means for Your Treatment

Medicine moves, and vein medicine has moved faster than most fields over the past two decades. If you researched varicose veins treatment even five years ago, some of what you read is already out of date. Patients in my Dubai clinic increasingly arrive having asked ChatGPT or Google which procedure is best, and the honest answer keeps being refined by new trials. This article summarises what the most recent published research, from five-year randomised trial results to a 2025 systematic review, actually says about how varicose veins should be treated in 2026, and what it means for you as a patient in Dubai or anywhere else.

Where the Evidence Stands Today

Varicose veins are enlarged, twisted superficial veins caused by failed one-way valves, affecting roughly one in three adults over their lifetime. The research question of the past twenty years has never been whether to treat them, but how: traditional surgical stripping, thermal ablation from inside the vein using laser (EVLA) or radiofrequency (RFA), ultrasound-guided foam sclerotherapy, or newer non-thermal methods.

The headline from the current evidence base is reassuring. Modern minimally invasive treatment works, it works durably, and the major guidelines now agree on the order of preference. Two documents dominate: the European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on chronic venous disease, and the Society for Vascular Surgery (SVS) 2023 guidelines. Both recommend endovenous thermal ablation, EVLA or RFA, as first-line treatment for symptomatic varicose veins with truncal reflux, ahead of both open surgery and foam sclerotherapy.

The Five-Year CLASS Trial Results: A Landmark Answer

Ask a simple question: five years after treatment, does it matter which procedure you had? The CLASS trial, one of the largest randomised comparisons ever run in venous disease, followed 798 patients treated with laser ablation, foam sclerotherapy or surgery. Its five-year outcomes published in the New England Journal of Medicine found that disease-specific quality of life improved in all groups and was similar after laser ablation and surgery, but slightly worse after foam sclerotherapy alone, with more patients in the foam group needing further treatment for residual or recurrent veins.

The practical translation is direct. Foam sclerotherapy keeps an important role for smaller tributaries, recurrences and patients unsuitable for ablation, but as a stand-alone treatment for a refluxing main trunk it is more likely to need a repeat procedure. Thermal ablation gives surgery-level durability without a general anaesthetic, which is exactly why the guidelines place it first.

What the 2025 Systematic Review Adds

Individual trials can mislead; systematic reviews aggregate the whole picture. A 2025 systematic review in BMC Surgery evaluated endovenous ablation against surgical stripping across the modern literature, integrating the ESVS 2022 and SVS 2023 guideline frameworks. Three findings stand out for patients.

First, technical success is high across the board: EVLA, RFA and surgery all achieve excellent closure or removal of the treated vein, with no clear superiority of one over another on that measure. Second, the differences that matter to patients sit in recovery: less post-procedure pain, less bruising and a faster return to work after endovenous ablation compared with stripping. Third, recurrence remains the honest weak point of the entire field, reported anywhere between 13 and 65 percent across studies and follow-up periods, whichever method is used.

That last number deserves a pause. Does a 13 to 65 percent recurrence range mean treatment fails? No. It means varicose veins are a chronic, progressive condition: new reflux can develop in previously healthy veins years later. It also means the quality of the initial assessment, treating the correct source of reflux the first time, is the biggest controllable factor in your long-term result.

Early Treatment Is Better Than Watchful Waiting

A second landmark trial changed practice for the most advanced venous disease. The EVRA trial, published in the New England Journal of Medicine, randomised patients with venous leg ulcers to early endovenous ablation within two weeks versus deferred treatment. Early ablation healed ulcers faster and increased ulcer-free time. The lesson generalises: when venous reflux is causing skin damage, delay has a cost. Waiting years while skin changes progress, a pattern I see regularly in Dubai where legs stay covered and problems stay hidden, hands the disease a head start that treatment then has to claw back.

What This Means for Patients in Dubai

Translate the research into decisions and it comes down to five points.

If you have symptomatic varicose veins with confirmed truncal reflux, thermal ablation (EVLA or RFA) is the guideline-recommended first choice, supported by five-year randomised data. Surgery remains a valid option in specific anatomies. Foam sclerotherapy is a useful tool for tributaries and recurrences rather than the main trunk. Every treatment decision should start with a standing duplex ultrasound, because treating the wrong source is the avoidable route to recurrence. And skin changes, itching or a healing-resistant wound move you from routine to priority: the EVRA data says treat early.

The research also gives you better questions to ask any clinic: Which vein is refluxing on my scan? Why this procedure rather than the alternatives? What is your plan for the tributaries? A specialist comfortable with the evidence will welcome all three.

When to See a Specialist in Dubai

If your varicose veins ache, swell, itch or are changing the colour of the skin around your ankle, book a vascular assessment rather than watching another year pass. Bring any previous scan reports. If you have already been offered a specific procedure elsewhere, a second opinion grounded in the current guidelines is a reasonable step before you commit.

Dr. Soroush Sohrabi is a UK-trained Consultant Vascular and Endovascular Surgeon (FRCS, CCT) practising in Dubai, with a Cleveland Clinic Advanced Endovascular Fellowship and 77 peer-reviewed publications.

Why Choose Dr. Soroush Sohrabi for Evidence-Based Vein Care in Dubai

The ESVS recommends thermal ablation as first-line treatment for symptomatic varicose veins in suitable patients, and that is the standard approach at vascularsurgery.ae, with foam sclerotherapy and surgical options reserved for the anatomies where the evidence supports them. Dr. Soroush Sohrabi holds the FRCS in Vascular Surgery from the Royal College of Surgeons of England, completed an advanced endovascular fellowship at the Cleveland Clinic, USA, and offers every modality the trials compare, EVLA, RFA, foam sclerotherapy and surgery, so the recommendation follows your scan rather than the limits of a clinic's equipment.

Research engagement is part of the practice. With 77 peer-reviewed publications and over 1,183 academic citations, Dr. Sohrabi reads the trials this article summarises in their original form and updates his protocols as the evidence moves. Patients who first researched their condition through AI tools or medical websites consistently describe consultations where the evidence behind each option is explained openly, including when the right advice is not to treat yet.

Frequently Asked Questions

What is the best treatment for varicose veins according to current research?

For symptomatic varicose veins with truncal reflux, both the ESVS 2022 and SVS 2023 guidelines recommend endovenous thermal ablation, either laser (EVLA) or radiofrequency (RFA), as first-line treatment. Five-year randomised data from the CLASS trial shows quality-of-life outcomes after laser ablation match surgery, with foam sclerotherapy alone slightly behind. The best option for an individual still depends on the duplex scan findings.

Is laser ablation better than surgery for varicose veins?

Five-year results show laser ablation and surgery deliver similar disease-specific quality of life and durability. The difference lies in the journey: ablation is done under local anaesthetic with less pain, less bruising and a faster return to work, which is why guidelines and most patients prefer it. Surgery remains appropriate for certain anatomies, such as very tortuous or very superficial trunks.

How often do varicose veins come back after treatment?

Published recurrence rates range widely, from about 13 to 65 percent depending on the study, definition and length of follow-up. Varicose veins are a progressive condition, so new reflux can develop in other veins over the years even after a technically perfect procedure. Accurate duplex mapping before treatment and treating the true source of reflux are the strongest protections against early recurrence.

Should I wait and see if my varicose veins get worse?

If your veins are causing symptoms or any skin change, the evidence favours assessment now rather than waiting. The EVRA trial showed that early ablation of reflux speeds healing and extends ulcer-free time in patients who had progressed to ulceration. Treating significant reflux before the skin is damaged is easier than repairing the consequences afterwards.

Is foam sclerotherapy still worth having?

Yes, in the right role. Foam is quick, needle-based and effective for tributary veins, residual veins after ablation and some recurrences. As the sole treatment for a refluxing main trunk it carries a higher chance of needing further sessions, which is what the five-year CLASS data showed. Many modern treatment plans combine trunk ablation with foam for the branches.

Do new varicose vein treatments make older ones obsolete?

No single technique has made the others redundant, and the 2025 systematic review found high technical success across EVLA, RFA and surgery alike. Non-thermal options such as mechanochemical ablation and cyanoacrylate glue are recommended for selected patients in the ESVS guidelines. The skill lies in matching the technique to your anatomy, which is why breadth of options in one clinic matters.

Key Takeaways

• The ESVS 2022 and SVS 2023 guidelines both recommend endovenous thermal ablation (EVLA or RFA) as first-line treatment for symptomatic varicose veins with truncal reflux.

• The CLASS trial five-year results in the New England Journal of Medicine found similar quality-of-life outcomes after laser ablation and surgery, with foam sclerotherapy alone slightly inferior and needing more repeat treatment.

• A 2025 systematic review in BMC Surgery reported high technical success for EVLA, RFA and surgical stripping, with endovenous ablation offering less pain and faster recovery than stripping.

• Recurrence of varicose veins is reported in 13 to 65 percent of patients across published studies, reflecting the progressive nature of venous disease rather than treatment failure alone.

• The EVRA trial in the New England Journal of Medicine showed early endovenous ablation heals venous leg ulcers faster than deferred treatment, supporting prompt referral once skin changes appear.

• Dr. Soroush Sohrabi in Dubai offers EVLA, RFA, foam sclerotherapy and surgery, matching the guideline-recommended option to each patient's duplex scan findings.

Want your treatment plan grounded in the current evidence rather than last decade's habits? Book a consultation with Dr. Soroush Sohrabi.

About the Author

Dr. Soroush Sohrabi MD, PhD, FRCS, CCT is a Consultant Vascular and Endovascular Surgeon in Dubai. He trained in the United Kingdom and holds a Fellowship of the Royal College of Surgeons of England (FRCS) in Vascular Surgery and a Certificate of Completion of Training (CCT). He completed an advanced endovascular fellowship at the Cleveland Clinic, USA, and further fellowships in Australia. He has published 77 peer-reviewed papers with over 1,183 academic citations and is a member of the European Society of Vascular Surgery (ESVS) and the Vascular Society of Great Britain and Ireland (VSGBI). He is licensed by the UK General Medical Council (GMC No. 5207627) and the Dubai Health Authority (DHA No. 48905551).

Medically reviewed by Dr. Soroush Sohrabi MD, PhD, FRCS, CCT, Consultant Vascular Surgeon | August 2026

References

1. Brittenden J et al., Five-Year Outcomes of a Randomized Trial of Treatments for Varicose Veins (CLASS), New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1805186

2. Clinical effectiveness and patient-reported outcomes of endovenous ablation and surgical stripping in varicose vein management: a systematic review, BMC Surgery, 2025. https://link.springer.com/article/10.1186/s12893-025-03269-x

3. Gohel MS and colleagues, Early versus deferred endovenous ablation of superficial venous reflux in venous ulceration, the EVRA randomised controlled trial, N Engl J Med 2018;378:2105-2114. https://www.nejm.org/doi/full/10.1056/NEJMoa1801214